Tanuja Chitnis, MD
Neurology · Boston, MANPI 1376517078
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $169,307 of the $202,397 with a category attached, or 83.7%. It is spread thinly across 16 manufacturers, the largest accounting for just 20.6%. Among neurology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 119 payments — averaging $1700.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$42K
- Novartis Pharma AG$33K
- Sanofi$32K
- Novartis$29K
- Siemens Medical Solutions USA, Inc.$15K
- Genentech USA, Inc.$14K
- plus $38K from 10 others
Across 89 payments — averaging $48,110 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.6M
- Genentech, Inc.$1.2M
- Novartis Pharma AG$620K
- Mallinckrodt Hospital Products Inc.$375K
- E.r. Squibb & Sons, L.L.C.$367K
- Mallinckrodt Enterprises LLC$80K
- plus $59K from 5 others
What the payments were for
- Consulting fees$169,30784%
- Speaking & faculty fees$9,9415%
- Travel & lodging$21,17310%
- Food & beverage$1,9711%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 20 | $41,744 |
| Novartis Pharma AG | 14 | $32,912 |
| Sanofi | 15 | $32,186 |
| Novartis | 21 | $28,806 |
| Siemens Medical Solutions USA, Inc. | 16 | $14,563 |
| Genentech USA, Inc. | 12 | $13,922 |
| Sanofi US Services Inc. | 5 | $13,825 |
| Biogen | 3 | $12,551 |
| Genentech, Inc. | 2 | $3,600 |
| Sanofi-aventis U.S. LLC | 2 | $2,417 |
| AstraZeneca | 1 | $1,920 |
| Roche Diagnostics International Ltd | 1 | $1,362 |
| Roche Products Limited | 1 | $900 |
| Banner Life Sciences, LLC | 1 | $900 |
| TG Therapeutics, Inc. | 3 | $784 |
| Travere Therapeutics, Inc. | 2 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCREVUS$38,856
- KESIMPTA$27,834
- ADVIA Centaur XP Analyzer$13,727
- Non-Covered Product$12,620
- AUBAGIO$10,480
- MAYZENT$6,061
- FTY720D_GILENYA_NEUROSCIENCE$5,423
- Enspryng$4,095
- BAF312A_MAYZENT_NEUROSCIENCE$3,828
- ARZERRA$2,552
- LEMTRADA$2,417
- Bafiertam$900
How this compares
$202,397 in reported general payments places this provider in the 95th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 23 | $190,343 |
| Plegridy PenPeginterferon Beta-1a | 18 | $150,410 |
| TecfideraDimethyl Fumarate | 12 | $105,552 |
| BetaseronInterferon Beta-1b | 12 | $100,810 |
| AubagioTeriflunomide | 11 | $94,374 |
| Dimethyl Fumarate | 31 | $31,601 |
| Teriflunomide | 16 | $18,022 |
| FingolimodFingolimod Hcl | 15 | $17,307 |
| Baclofen | 44 | $1,711 |
| Riluzole | 18 | $1,393 |
| Modafinil | 22 | $876 |
| AmantadineAmantadine Hcl | 11 | $793 |
| Gabapentin | 30 | $656 |
| Memantine Hcl | 12 | $527 |
| Levetiracetam | 14 | $483 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenTecfidera | $12,551 | $105,55212 claims |
| SanofiAubagio | $32,186 | $94,37411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 761 neurology providers in Massachusetts.
Other neurology in Boston
- Christopher WrightBoston$2.5M
- Thomas ScammellBoston$617K
- Alfred SandrockBoston$490K
- Pushpa NarayanaswamiBoston$420K
- Roy FreemanBoston$390K
- Michael LevyBoston$387K
- Leeann BurtonBoston$325K
- Ilena GeorgeBoston$316K
- Andrew BudsonBoston$304K
- Denis BalabanBoston$297K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.